- Overshooting 1.5C risks 'irreversible' climate impact: study
- Demis Hassabis, from chess prodigy to Nobel-winning AI pioneer
- Global stocks diverge as Chinese shares tumble
- Time runs out in Florida to flee Hurricane Milton
- Chad issues warning ahead of more devastating floods
- Creator's death no bar to new 'Dragon Ball' products
- Chinese stocks tumble on lack of fresh stimulus
- Trio wins chemistry Nobel for protein design, prediction
- Braving war: Lebanon's 'badass' airline defies odds
- US weighs Google breakup in landmark trial
- Chinese stocks tumble on stimulus upset, Asia tracks Wall St higher
- 7-Eleven owner confirms new takeover offer from Couche-Tard
- A US climate scientist sees hurricane Helene's devastation firsthand
- Can carbon credits help close coal plants?
- Boeing suspends negotiations with striking workers
- 7-Eleven owner's shares spike on report of new buyout offer
- Your 'local everything': what 7-Eleven buyout battle means for Japan
- AI-aided research, new materials eyed for Nobel Chemistry Prize
- The US economy is solid: Why are voters gloomy?
- Scientists sound AI alarm after winning physics Nobel
- Nobel-winning physicist 'unnerved' by AI technology he helped create
- Trump secretly sent Covid tests to Putin: Bob Woodward book
- Neural networks, machine learning? Nobel-winning AI science explained
- Boeing delivers 27 MAX jets in September despite strike
- Stock markets diverge as Hong Kong sinks, oil prices fall
- US trade gap narrowest in five months as imports slip
- Stay and 'you are going to die': Florida braces for next hurricane
- Geoffrey Hinton, soft-spoken godfather of AI
- Duo wins Physics Nobel for 'foundational' AI breakthroughs
- German 'Maddie' suspect could be free in 2025 after cleared of separate sex crimes
- China slaps provisional tariffs on EU brandy imports
- Duo wins Physics Nobel for key breakthroughs in AI
- German 'Maddie' suspect could be free soon after cleared of separate sex crimes
- China says to take anti-dumping measures against EU brandy imports
- China stocks rally fizzles on stimulus worries amid Asia retreat
- China stocks rally peters out on stimulus worries amid Asia retreat
- Taiwan's Foxconn says building world's largest 'superchip' plant
- Nobel literature jury may go for non-Western writer
- From Bolivia to Indonesia, deforestation continues apace
- China holds off on fresh stimulus but 'confident' will hit growth target
- German suspect in 'Maddie' case faces verdict in sex crimes trial
- Top economic official 'confident' China will hit 2024 growth target
- COP29 fight looms over climate funds for developing world
- Shanghai stocks soar to extend stimulus rally amid Asia-wide drop
- Will Tesla's robotaxi reveal live up to hype?
- 'Invisibility' and quantum computing tipped for physics Nobel
- Oil prices extend gains on Mideast tensions, Wall Street falls
- 'Dark day': Victims mourned around the globe on Oct. 7 anniversary
- Mission to probe smashed asteroid launches despite hurricane
- Oil prices extend gains on Mideast tensions, Wall Street slips
RIO | -0.68% | 66.21 | $ | |
CMSC | 0.28% | 24.64 | $ | |
NGG | -0.34% | 65.675 | $ | |
BTI | 0.55% | 35.415 | $ | |
GSK | 0.45% | 38.19 | $ | |
SCS | 2.44% | 13.1 | $ | |
BCE | -0.15% | 33.46 | $ | |
BP | -0.41% | 31.9 | $ | |
BCC | 0.45% | 142.665 | $ | |
RYCEF | -1.01% | 6.9 | $ | |
JRI | 0.3% | 13.2 | $ | |
CMSD | -0.11% | 24.8248 | $ | |
RBGPF | -2.48% | 59.33 | $ | |
RELX | -0.09% | 46.6 | $ | |
AZN | 0.12% | 76.965 | $ | |
VOD | 0.46% | 9.705 | $ |
Pharma lobby blasts 'stupid' pandemic patent plans
Stripping patent protection from Covid-19 treatments is a "mind-bogglingly stupid" idea, the head of a leading pharmaceutical lobby said Wednesday, warning that the move would put industry innovation at risk.
Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), said the industry was still working on more effective Covid vaccines and treatments.
But Cueni said manufacturers would not risk ploughing investment into potential products if their intellectual property (IP) rights could be stripped away.
Cueni told reporters it would be "seriously dangerous" to move from voluntary knowledge-sharing seen during the pandemic to a "coercive" situation.
He added that when knowledge and technology is shared, generic manufacturers were still reliant on close support from the patent holders.
At the World Health Organization, plans are being drawn up for what could be a legally binding treaty on future pandemic preparedness.
Meanwhile, World Trade Organization members are discussing broadening a temporary IP waiver for producing Covid vaccines, agreed in June 2022, to include tests and treatments.
"That debate should simply have been closed," Cueni said.
He said more than 800 potential Covid-19 treatments were being researched -- and of approved treatments, around two-thirds were pre-existing medicines that companies had tested to see if they worked against Covid.
If the patent on the Covid part of any medicine is removed, there is "no way... to protect the original part", he said.
"I have heard many companies say we would never have considered risking our core business and checking if it works" if they risked losing the protection that encouraged them to invest in at-risk research.
Therefore, an IP waiver "potentially undermining what worked so well in this pandemic is basically mind-bogglingly stupid", Cueni said.
He also said proposals to waive patents on tests were "ludicrous" as there was no generic market for diagnostics.
- Vaccine equity vow -
Cueni said IFPMA members were concerned about ensuring that what worked well in the Covid-19 response is not lost or compromised for future pandemic preparedness.
He said manufacturers needed fast, unhindered access to respond to emerging pathogens.
But he acknowledged that pharma firms needed to learn from "what didn't work well -- that is equitable roll-out" of vaccines.
"We need to make sure that dose-sharing is something we build in from day one," he said.
Cueni said there needed to be greater geographic diversity in manufacturing, with most vaccines being produced only in the United States, Europe, China and India.
"Even if that works, you will still need to open borders and remove trade barriers," he said, noting that supply chain problems could slow production.
And even then, "we need to work on country readiness because once we had not just sufficient supply of vaccines but an over-supply of vaccines, we still didn't see the jabs getting into the arms of people".
- Cost claim -
With the pandemic now entering its fourth year, Cueni said major manufacturers were busy working on improved jabs and treatments.
He hoped that future vaccines would offer longer-lasting protection.
"It would be nice if one jab per year would suffice," he said.
As for the profits made by the pharmaceutical industry during the pandemic, Cueni said: "When you look at how much Covid-19 cost the global economy, the cost of the treatments or the vaccines was just a tiny fraction of that."
J.Bondarev--CPN